{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A127", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004204, "timestamp_received": "2026-09-25T00:14:00.633511+00:00Z", "timestamp_returned": "2026-09-25T00:14:00.637715+00:00Z", "trace_id": "d8eb3305-0b7d-4d70-8748-1e2082f7587c" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:balversa:0:3", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2024-01-19:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2024-01-19", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:balversa", "type": "Document", "documentType": "Regulatory approval", "name": "Balversa (erdafitinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Janssen Products, LP.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Balversa", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "erdafitinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 212018, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-01-19", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:127", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:BLCA", "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA" ] } }, "objectTherapeutic": { "id": "tx:ncit:C103273", "conceptType": "Therapy", "name": "Erdafitinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2123125", "code": "2123125", "name": "erdafitinib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2123125" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1511250", "code": "1511250", "name": "erdafitinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1511250" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:787731007", "code": "787731007", "name": "Erdafitinib", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=787731007&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:37204108", "code": "37204108", "name": "Erdafitinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/37204108" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "FGFR inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C103273", "code": "C103273", "name": "Erdafitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:102", "present": true, "subject": { "id": "bmkr:102", "type": "CategoricalVariant", "name": "FGFR3 p.Y373C", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.UHA6S3oE8Ts_WI51w5noSpXhSlvNEjHu", "type": "Allele", "name": "NP_000133.1:p.Tyr373Cys", "aliases": [ "NP_000133.1:p.Y373C", "FGFR3 p.Y373C" ], "description": "VRS variation of NP_000133.1:p.Tyr373Cys", "digest": "UHA6S3oE8Ts_WI51w5noSpXhSlvNEjHu", "expressions": [ { "syntax": "hgvs.p", "value": "NP_000133.1:p.Tyr373Cys", "extensions": [ { "name": "hgvs.p_short", "value": "p.Y373C" } ] } ], "location": { "id": "ga4gh:SL.g33H1Cf5jJONJO2upu64mfFipyfSK6MZ", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 373 of the Refseq protein NP_000133.1, which is the protein product of the MANE Select coding transcript for FGFR3 (refseq:NM_000142.5).", "digest": "g33H1Cf5jJONJO2upu64mfFipyfSK6MZ", "sequenceReference": { "id": "ga4gh:SQ.xO86teDIIalLkqprCQaXyuvdPqvBxBG3", "type": "SequenceReference", "name": "NP_000133.1", "aliases": [ "ensembl:ENSP00000260795.2", "ga4gh:SQ.xO86teDIIalLkqprCQaXyuvdPqvBxBG3", "refseq:NP_000133.1" ], "description": "The protein product of the MANE Select coding transcript for FGFR3 (refseq:NM_000142.5), corresponding to the Refseq protein accession NP_000133.1.", "moleculeType": "protein", "refgetAccession": "SQ.xO86teDIIalLkqprCQaXyuvdPqvBxBG3", "residueAlphabet": "aa" }, "start": 372, "end": 373, "sequence": "Y" }, "state": { "type": "LiteralSequenceExpression", "sequence": "C" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3690", "conceptType": "Gene", "name": "FGFR3", "primaryCoding": { "id": "coding:hgnc:3690", "code": "HGNC:3690", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000068078", "code": "ENSG00000068078", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000068078" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:2261", "code": "2261", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/2261" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_000142.5", "code": "NM_000142.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "4" }, { "name": "start_position", "value": 1806099 }, { "name": "end_position", "value": 1806099 }, { "name": "reference_allele", "value": "A" }, { "name": "alternate_allele", "value": "G" }, { "name": "cdna_change", "value": "c.1118A>G" }, { "name": "protein_change", "value": "p.Y373C" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 8 }, { "name": "rsid", "value": "rs121913485" }, { "name": "hgvsg", "value": "4:g.1806099A>G" }, { "name": "hgvsc", "value": "ENST00000260795.2:c.1118A>G" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:balversa:0", "type": "Indication", "description": "BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2024-01-19:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2024-01-19", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:balversa", "type": "Document", "documentType": "Regulatory approval", "name": "Balversa (erdafitinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Janssen Products, LP.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Balversa", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "erdafitinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 212018, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-01-19", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }